Meri Rogava

Northwell Health — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

16h-index3.4kcitations55works9.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Melanoma and MAPK Pathways(15), Cancer Immunotherapy and Biomarkers(12), Immunotherapy and Immune Responses(10), CAR-T cell therapy research(8), Synthesis and biological activity(7)

Publications55 total

362 Dissecting immune evasion in pediatric brain tumors through organoid models and multiplex immune profiling
Regular and Young Investigator Award Abstracts·2025Open Access
Single-cell and spatial genomic landscape of non-small cell lung cancer brain metastases
Nature Medicine·2025· 30 citedOpen Access
Suppressing PD-L1 Expression via AURKA Kinase Inhibition Enhances Natural Killer Cell-Mediated Cytotoxicity against Glioblastoma
Cells·2024· 2 citedOpen Access
Mapping variant effects on anti-tumor hallmarks of primary human T cells with base-editing screens
Nature Biotechnology·2024· 27 citedOpen Access
Abstract 5360: Relief of chromosomal instability-induced cGAS-STING signaling sensitizes <i>STK11</i>-mutant non-small cell lung cancer to immune checkpoint blockade
Cancer Research·2024
Abstract 6598: Inhibition of cGAS as a strategy to restore anti-tumor immunity response to STING agonist in chromosomally unstable tumors
Cancer Research·2024
Loss of Pip4k2c confers liver-metastatic organotropism through insulin-dependent PI3K-AKT pathway activation
Nature Cancer·2024· 18 citedOpen Access
Author Correction: Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I–III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial
Nature Communications·2024Open Access
Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I–III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial
Nature Communications·2023· 38 citedOpen Access
KLRG1 marks tumor-infiltrating CD4 T cell subsets associated with tumor progression and immunotherapy response
Journal for ImmunoTherapy of Cancer·2023· 18 citedOpen Access
Association of circulating CD103<sup>+</sup> T cells with major pathological response in a randomized phase 2 trial of neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small cell lung cancer.
Journal of Clinical Oncology·2023
Systematic elucidation and pharmacological targeting of tumor-infiltrating regulatory T cell master regulators
Cancer Cell·2023· 49 citedOpen Access
Abstract 3514: A genetic-metabolic circuit of liver-specific metastatic organotropism
Cancer Research·2023
Supplementary Data from Inhibition of Haspin Kinase Promotes Cell-Intrinsic and Extrinsic Antitumor Activity
2023Open Access
Video from Inhibition of Haspin Kinase Promotes Cell-Intrinsic and Extrinsic Antitumor Activity
2023Open Access
Supplementary Table 1 from Inhibition of Haspin Kinase Promotes Cell-Intrinsic and Extrinsic Antitumor Activity
2023Open Access
Video from Inhibition of Haspin Kinase Promotes Cell-Intrinsic and Extrinsic Antitumor Activity
2023Open Access
Supplementary Data from Inhibition of Haspin Kinase Promotes Cell-Intrinsic and Extrinsic Antitumor Activity
2023Open Access
Video from Inhibition of Haspin Kinase Promotes Cell-Intrinsic and Extrinsic Antitumor Activity
2023Open Access
Supplementary Figures from Inhibition of Haspin Kinase Promotes Cell-Intrinsic and Extrinsic Antitumor Activity
2023Open Access
page 1 of 3Next →

Frequent Co-authors

Benjamin Izar(30), Johannes C. Melms(27), Thomas Tüting(18), Dirk Schadendorf(16), Adrienne Luoma(15), Tobias Bald(15), Michael Hölzel(15), Nicole Glodde(14), Patricia Ho(13), Jennifer Landsberg(13), Peter K. Sorger(13), Kai W. Wucherpfennig(13), Stefanie Riesenberg(12), Amit Dipak Amin(11), Shaolin Mei(11), Titus J. Brinker(11), Caitlin E. Mills(11), Albert J. Becker(11), Sreeram Vallabhaneni(10), Clarence Yapp(10)